Development, Immune Response and Radiology - Clinical Research Informer

Ginkgo Bioworks to discover and develop novel vaccine adjuvants

Drug Discovery World

FEBRUARY 20, 2024

A five-year contract totalling up to $31 million including programme options has been awarded to Ginkgo Bioworks to discover and develop next-generation vaccine adjuvants. The post Ginkgo Bioworks to discover and develop novel vaccine adjuvants appeared first on Drug Discovery World (DDW).

Vaccination

Vaccination Vaccine Development Immune Response

Symbiotica and Quidel Score FDA Authorizations for COVID-19 Tests

XTalks

APRIL 7, 2021

COVID-19 antibody tests can help identify people who may have had prior COVID-19 infection, and importantly, asymptomatic individuals with a developing or current infection. The tests do not detect the SARS-CoV-2 virus itself, and hence should not be used for diagnostic purposes.

Antibody

Antibody Immune Response Radiology Marketing

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance the development of INO-4800. It will be funded by the U.S.

DNA

DNA Vaccination Vaccine Immune Response

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial. W911QY-21-9-0001.

Antibody

Antibody In-Vivo Vaccination Vaccine

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

The Pharma Data

MARCH 25, 2022

” Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “Today’s positive CHMP recommendation represents a significant step forward in our ongoing efforts to introduce additional, important preventative measures for people in Europe at higher risk of developing COVID-19. W911QY-21-9-0001.

Antibody

Antibody In-Vivo Medicine Vaccination

Low-dose radiotherapy combined with immunotherapy eradicates metastatic cancer in mice

Bioengineer

JULY 15, 2021

.” Immunotherapy has revolutionized cancer treatment by helping patients’ immune systems fight off cancer. Boosted by the immunotherapy, the immune cells attacked the cancer cells that had been damaged by the radiotherapy. This agent was developed by one of the co-authors, Jamey Weichert, Ph.D., ” ###.

Medicine

Medicine Clinical Trials Clinical Trials Scientist

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study.

Immune Response

Immune Response Vaccination Vaccine Trials

Who are the AACR Scientific Achievement Award winners?

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Genetics

Genetics Research Medicine Clinical Research

3 Newest COVID-19 Tests Authorized by the FDA

XTalks

MARCH 10, 2021

Along with COVID-19 vaccine authorizations, the US Food and Drug Administration (FDA) remains committed to increasing access to COVID-19 tests and supporting their development, having authorized three new tests recently for emergency use. The products encompass molecular, antigen and T cell-based testing approaches.

Protein

Protein RNA Antibody Production

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

The Pharma Data

AUGUST 22, 2021

More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis.There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442.

Trials

Trials Antibody Vaccination Vaccine

Research Roundup: UK Strain of COVID-19 and More

The Pharma Data

DECEMBER 23, 2020

The other, 69-70, leads to the loss of two amino acids in the spike protein and seems to help viruses evade the immune response in some immunocompromised patients. It is also the primary focus of the vaccines developed by Pfizer-BioNTech and Moderna and other companies. In research in South Africa in B.1.1.7,

Research

Research Protein Gene Vaccination

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

And in truth, the companies the White House picked were pretty savvy as several are current front-runners in the race to develop a vaccine. The company is also in collaboration with Ridgeback Biotherapeutics to develop a novel oral antiviral treatment for COVID-19. helped protect COVID-19 patients against developing severe disease.

Vaccination

Vaccination Vaccine Antibody Life Science

Clinical Research Informer

Ginkgo Bioworks to discover and develop novel vaccine adjuvants

Symbiotica and Quidel Score FDA Authorizations for COVID-19 Tests

Trending Sources

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

Low-dose radiotherapy combined with immunotherapy eradicates metastatic cancer in mice

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

Who are the AACR Scientific Achievement Award winners?

3 Newest COVID-19 Tests Authorized by the FDA

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

Research Roundup: UK Strain of COVID-19 and More

COVID-19 Pandemic Coverage

Stay Connected